Amsterdam UMC
Verified site
Amsterdam, The Netherlands
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
The study focuses on adults with type 2 diabetes whose blood sugar control remains insufficient despite standard therapy. Participants will continue their usual medication and will receive either the investigational drug dasatinib taken by mouth, the background medication semaglutide injected under the skin, or a matching placebo. The goal is to see whether adding the senolytic agent dasatinib can lower markers of cellular senescence (the process where cells stop dividing and can cause tissue problems) and inflammation (the body’s response that can damage tissues), and improve glucose tolerance (how well the body handles sugar after a meal).
During the trial, participants will attend regular visits over about 20 weeks. At the start and at the end, small samples of fat and muscle tissue will be taken to measure senescence markers, and blood samples will be checked for related proteins. A sugar‑drink test will be performed to assess how quickly blood sugar rises and falls, while a wearable device will record daily glucose patterns. Standard laboratory tests will track changes in HbA1c (average blood sugar over the past few months), insulin sensitivity (how well the body responds to insulin), and beta-cell function (the ability of the pancreas to release insulin). Participants will also complete quality‑of‑life questionnaires to capture any changes in overall well‑being.
The trial runs in 9 steps – from screening to follow-up. Each step says what happens and what the team monitors.
7 criteria
14 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Amsterdam, The Netherlands
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not yet recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is a medication that helps remove damaged or aged cells, known as senescent cells, from the body. In this study, participants will take dasatinib in addition to their usual diabetes treatment to see if it can lower inflammation and improve how the body handles sugar. Researchers hope that by clearing these unhealthy cells, the drug may help protect the pancreas and improve overall blood‑sugar control in people with type 2 diabetes.
is a medicine that is already used to treat type 2 diabetes. It is given as a tiny injection under the skin and works by helping the pancreas release more insulin after meals, reducing the amount of sugar the liver makes, and slowing down how quickly food leaves the stomach. In this trial, semaglutide is used as the background therapy so that all participants have a standard diabetes treatment while the study tests whether adding dasatinib provides extra benefit.
Dasatinib is taken as a film‑coated tablet that is swallowed by mouth. It is an approved cancer medicine that is now being studied for its ability to remove old, harmful cells that contribute to inflammation. Its main use is for certain types of leukemia, and it works by blocking signals that tell damaged cells to keep growing. It belongs to the class of tyrosine‑kinase inhibitors and is considered a senolytic agent in research.
Semaglutide is provided as a liquid that is injected under the skin using a pre‑filled pen. It is a widely approved treatment for type 2 diabetes and also for weight management. It works by mimicking a natural hormone that helps the pancreas release insulin and reduces appetite. It is classified as a GLP‑1 receptor agonist.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.